Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.575 USD | +2.10% | +4.94% | +45.58% |
Financials (USD)
Sales 2024 * | 334M | Sales 2025 * | 390M | Capitalization | 1.49B |
---|---|---|---|---|---|
Net income 2024 * | 67M | Net income 2025 * | 114M | EV / Sales 2024 * | 4.47 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 3.83 x |
P/E ratio 2024 * |
21.8
x | P/E ratio 2025 * |
12.9
x | Employees | 624 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.46% |
Latest transcript on ADMA Biologics, Inc.
1 day | -0.31% | ||
1 week | +3.87% | ||
Current month | -2.42% | ||
1 month | +0.78% | ||
3 months | +26.77% | ||
6 months | +103.15% | ||
Current year | +42.48% |
Managers | Title | Age | Since |
---|---|---|---|
Adam Grossman
CEO | Chief Executive Officer | 47 | 06-06-01 |
Compliance Officer | 37 | 10-12-31 | |
Skyler Bloom
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Lawrence Guiheen
BRD | Director/Board Member | 73 | 12-07-23 |
Bryant Fong
BRD | Director/Board Member | 51 | 12-04-30 |
Steven Elms
CHM | Chairman | 60 | 06-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.07% | 0 M€ | 0.00% | - | |
0.04% | 0 M€ | 0.00% | - | |
0.01% | 9 M€ | +5.51% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 6.58 | +2.17% | 732 196 |
24-04-25 | 6.44 | -0.31% | 1,531,854 |
24-04-24 | 6.46 | -1.22% | 1,716,472 |
24-04-23 | 6.54 | +5.48% | 2,752,319 |
24-04-22 | 6.2 | -1.12% | 2,301,644 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+42.48% | 1.49B | |
-4.66% | 87.53B | |
+2.63% | 40.42B | |
-21.76% | 29.48B | |
+55.83% | 25.43B | |
-14.78% | 15.59B | |
-18.49% | 11.49B | |
-15.61% | 11.1B | |
-44.02% | 11.3B | |
+4.42% | 8.75B |
- Stock Market
- Equities
- ADMA Stock